Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?

UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals (NYSE: TEVA  ) , a company that UBS believes will benefit from continued patent expirations , and generic drug introductions in the coming years. Hence, it's a long-term catalyst that UBS foresees, but in looking at Teva's competitors Actavis plc (NYSE: AGN  ) and Mylan Inc (NASDAQ: MYL  ) , is it really the best opportunity of the bunch?

Underperformance equals value?
Teva, Actavis, and Mylan are all generic drug manufacturers, with Actavis and Mylan's stock easily outperforming Teva during the last five years.

ACT Chart

ACT data by YCharts

The generic drug market as a whole has benefited greatly from an era known as the patent cliff, a period between 2011 and 2016 where more than $130 billion of brand drug sales lose patent protection.

While many of the biggest drugs have already lost patent protection, other blockbusters such as Nexium, Celebrex, Cymbalta, Abilify, and Crestor are still on tap to lose protection. Hence, UBS must think that Teva's underperformance equals value now.

Why has Teva underperformed its peers?
In looking at Teva, Actavis, and Mylan from a fundamental perspective, the reasons for the former's underperformance couldn't be clearer. For one, the company's 8% annualized revenue growth rate over the last three years lags its peers; Actavis has grown at a 34.5% rate over the last three years.

While much of this growth comes from acquisitions, Actavis has also hit the jackpot with high profile generic drug launches, including Suboxone, Lamictal, Nuvigil, Onglyza, and Lidoderm in the last year.

For Mylan, its 8.2% growth rate over the last three years is marginally better than Teva, but the stock's near 20% gains this year can be traced to catalysts including its victory in gaining rights to the 50mg generic version for the blockbuster Celebrex later this year.  Also, Mylan got a big win at the expense of Teva.

Specifically, Teva is not just a generic drug manufacturer, but also sells brand products like the blockbuster multiple sclerosis drug Copaxone. In 2013, Copaxone generated $3.2 billion in the U.S. alone with growth of 11% year-over-year . In other words, this one drug accounts for more than 15% of total sales.

Teva is in the process of losing patent protection on Copaxone, but has been fighting relentlessly to protect some pieces of the blockbuster's revenue. Already, back in May Teva lost a court case to delay the generic form of Copaxone,  which means that Mylan will gain rights to sell a 20mg dosage of the drug. Now, the company's only hope lies in switching patients to a longer lasting 40mg dose, but the problem is that generic forms will still be cheaper, even with the dosing advantage.

As a result, Teva will lose at least a portion of its Copaxone revenue immediately, and a probably more. No doubt in part due to gains at Teva's expense,  Mylan's revenue growth is expected to accelerate in 2014 to 12.7% while analysts expect Teva's revenue to be flat in 2014 and down slightly in 2015.

Is Teva that cheap?
In retrospect, while Mylan and Actavis benefit from the patent cliff, Teva is about to feel the pinch of losing significant annual revenue from one single drug. Therefore, its generic business may create growth, but the losses from Copaxone will essentially make those generic gains fundamentally irrelevant, putting Teva in a multi-year slump of flat growth.

With that said, why would UBS call it the main beneficiary of the patent cliff, and not Mylan or Actavis? From a fundamental growth outlook, it significantly lags its peers into the next couple years, which is when the period will end. Therefore, UBS's call has to be valuation-related, right?


Forward P/E Ratio







As you can see, Teva does trade at a cheaper multiple than either Mylan or Actavis, but the real question is whether that discount is enough to justify its lack of growth. Essentially, you can pay 11.3 times forward earnings for a company that will have no growth over the next two years (per analyst estimates), or 13 times next year's earnings for a company that'll grow revenue 45% and 23%, respectively, in the same period in Actavis .

Foolish Thoughts
With all things considered, UBS might have got this one wrong, discounting the fact that Copaxone's lost patent means Teva will struggle even with the tailwind of the patent cliff over the next two years. Meanwhile, Mylan and Actavis both look cheap, and while the former has had some nice generic wins in recent months, Actavis' growth is unprecedented. As a result, at just 13 times next year's earnings, Actavis looks to be the best-in-class stock, one that still has a lot to gain.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 24, 2014, at 10:26 PM, erich69 wrote:

    You forgot the best generic manufacturer of them all TARO. It would have returned 1,400% return in 5 years. Sometimes the best investments are often the ones that are quietly making a lot of money that receive no news coverage.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3042215, ~/Articles/ArticleHandler.aspx, 9/4/2015 9:40:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Nichols

Brian Nichols is the author of "5 Simple Steps to Find the Next Top-Performing Stock: How to Identify Investments that Can Double Quickly for Personal Success (2014)" and "Taking Charge With Value Investing (McGraw-Hill, 2013)". Brian is a value investor, but emphasizes psychology in his analysis. Brian studied psychology in undergrad, and uses his experience to find illogical value in the market. Brian covers technology and consumer goods for Motley Fool. Brian also updates all of his new and current positions in his Motley Fool CAPs page. Follow Brian on Twitter and like his page on Facebook for investment conversations and recent stories.

Today's Market

updated 24 minutes ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:02 PM
AGN $293.74 Down -3.70 -1.24%
Allergen PLC CAPS Rating: ****
MYL $48.05 Up +0.63 +1.33%
Mylan CAPS Rating: *****
TEVA $63.44 Down -0.68 -1.06%
Teva Pharmaceutica… CAPS Rating: *****